Equities research analysts expect Axsome Therapeutics Inc (NASDAQ:AXSM) to post ($0.32) earnings per share for the current quarter, Zacks reports. Zero analysts have made estimates for Axsome Therapeutics’ earnings. Axsome Therapeutics posted earnings per share of ($0.30) in the same quarter last year, which would indicate a negative year over year growth rate of 6.7%. The business is scheduled to issue its next quarterly earnings report on Wednesday, August 8th.
On average, analysts expect that Axsome Therapeutics will report full year earnings of ($1.08) per share for the current year, with EPS estimates ranging from ($1.11) to ($1.04). For the next financial year, analysts forecast that the company will post earnings of ($0.68) per share, with EPS estimates ranging from ($1.11) to ($0.24). Zacks’ EPS calculations are a mean average based on a survey of analysts that that provide coverage for Axsome Therapeutics.
Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings results on Tuesday, May 8th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.09.
Shares of Axsome Therapeutics traded down $0.25, reaching $3.00, on Tuesday, MarketBeat reports. The stock had a trading volume of 914,202 shares, compared to its average volume of 142,988. Axsome Therapeutics has a 1 year low of $2.05 and a 1 year high of $6.45. The company has a market cap of $82.84 million, a price-to-earnings ratio of -2.42 and a beta of -0.31. The company has a current ratio of 2.95, a quick ratio of 2.95 and a debt-to-equity ratio of 0.47.
Hedge funds have recently bought and sold shares of the stock. Goldman Sachs Group Inc. bought a new position in shares of Axsome Therapeutics in the fourth quarter worth approximately $238,000. Renaissance Technologies LLC bought a new position in shares of Axsome Therapeutics in the fourth quarter worth approximately $271,000. A.R.T. Advisors LLC bought a new position in shares of Axsome Therapeutics in the first quarter worth approximately $145,000. Sabby Management LLC bought a new position in shares of Axsome Therapeutics in the first quarter worth approximately $199,000. Finally, Sio Capital Management LLC bought a new position in shares of Axsome Therapeutics in the first quarter worth approximately $474,000. Institutional investors own 16.49% of the company’s stock.
About Axsome Therapeutics
Axsome Therapeutics, Inc, a clinical stage biopharmaceutical company, is developing novel therapies for central nervous system (CNS) disorders. Its product candidate portfolio includes AXS-05, AXS-09, AXS-02, AXS-07, and AXS-06. AXS-05 is in the Phase III clinical trial in treatment resistant depression and in agitation associated with Alzheimer's disease, as well as in the Phase II clinical trial for smoking cessation.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.